Low-molecular-weight heparins (LMWHs) are strategically important products for the RF and their consumption volumes have shown a consistent growth every year. These products are manufactured only abroad and this fact explains their high costs. Meantime, major consumers of the finished dosage from include the RF public health sector and the individuals who need relatively inexpensive and high-quality medications.

As of today, no domestically manufactured analogs of LMWHs have been registered with the RF and therefore more and more efforts are made to develop technology and to launch production of this substance.

The joint stock research company (ZAO) “Pharm-Holding” is involved in the design and development of innovative gene engineered products, including low-molecular-weight heparin derivatives. The manufacture of developed products will be started at the “Geopharm” production sites located in Pushkino and Obolensk (in partnership with the Joint Stock Company (OAO) “National Biotechnologies”). 

An integrated cycle of LMWH production (including substance) will be set up in the facility of the Joint Stock Company (OAO “Biosynthesis”). A leading Russian research center – the FSUE “GosNIIgenetika” (the Federal State Unitary Enterprise “State Research Institute of Genetics and Selection of Industrial Microorganisms”) is considered as a potential partner for developing and executing product manufacture processes.